174 related articles for article (PubMed ID: 12553073)
1. Preparation of Gc protein-derived macrophage activating factor (GcMAF) and its structural characterization and biological activities.
Mohamad SB; Nagasawa H; Uto Y; Hori H
Anticancer Res; 2002; 22(6C):4297-300. PubMed ID: 12553073
[TBL] [Abstract][Full Text] [Related]
2. Effect of the Gc-derived macrophage-activating factor precursor (preGcMAF) on phagocytic activation of mouse peritoneal macrophages.
Uto Y; Yamamoto S; Takeuchi R; Nakagawa Y; Hirota K; Terada H; Onizuka S; Nakata E; Hori H
Anticancer Res; 2011 Jul; 31(7):2489-92. PubMed ID: 21873164
[TBL] [Abstract][Full Text] [Related]
3. β-Galactosidase treatment is a common first-stage modification of the three major subtypes of Gc protein to GcMAF.
Uto Y; Yamamoto S; Mukai H; Ishiyama N; Takeuchi R; Nakagawa Y; Hirota K; Terada H; Onizuka S; Hori H
Anticancer Res; 2012 Jun; 32(6):2359-64. PubMed ID: 22641675
[TBL] [Abstract][Full Text] [Related]
4. Association of the macrophage activating factor (MAF) precursor activity with polymorphism in vitamin D-binding protein.
Nagasawa H; Sasaki H; Uto Y; Kubo S; Hori H
Anticancer Res; 2004; 24(5C):3361-6. PubMed ID: 15515432
[TBL] [Abstract][Full Text] [Related]
5. Gc protein (vitamin D-binding protein): Gc genotyping and GcMAF precursor activity.
Nagasawa H; Uto Y; Sasaki H; Okamura N; Murakami A; Kubo S; Kirk KL; Hori H
Anticancer Res; 2005; 25(6A):3689-95. PubMed ID: 16302727
[TBL] [Abstract][Full Text] [Related]
6. Gc protein-derived macrophage activating factor (GcMAF): isoelectric focusing pattern and tumoricidal activity.
Mohamad SB; Nagasawa H; Sasaki H; Uto Y; Nakagawa Y; Kawashima K; Hori H
Anticancer Res; 2003; 23(6a):4451-7. PubMed ID: 14666733
[TBL] [Abstract][Full Text] [Related]
7. Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta-galactosidase of B cells and sialidase of T cells.
Yamamoto N; Kumashiro R
J Immunol; 1993 Sep; 151(5):2794-802. PubMed ID: 8360493
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor.
Yamamoto N; Naraparaju VR
Cancer Res; 1997 Jun; 57(11):2187-92. PubMed ID: 9187119
[TBL] [Abstract][Full Text] [Related]
9. Degalactosylated/desialylated human serum containing GcMAF induces macrophage phagocytic activity and in vivo antitumor activity.
Kuchiike D; Uto Y; Mukai H; Ishiyama N; Abe C; Tanaka D; Kawai T; Kubo K; Mette M; Inui T; Endo Y; Hori H
Anticancer Res; 2013 Jul; 33(7):2881-5. PubMed ID: 23780974
[TBL] [Abstract][Full Text] [Related]
10. Structurally well-defined macrophage activating factor derived from vitamin D3-binding protein has a potent adjuvant activity for immunization.
Yamamoto N; Naraparaju VR
Immunol Cell Biol; 1998 Jun; 76(3):237-44. PubMed ID: 9682967
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D3-binding protein as a precursor for macrophage activating factor in the inflammation-primed macrophage activation cascade in rats.
Yamamoto N; Naraparaju VR
Cell Immunol; 1996 Jun; 170(2):161-7. PubMed ID: 8660814
[TBL] [Abstract][Full Text] [Related]
12. Role of vitamin D3-binding protein in activation of mouse macrophages.
Yamamoto N; Naraparaju VR
J Immunol; 1996 Aug; 157(4):1744-9. PubMed ID: 8759764
[TBL] [Abstract][Full Text] [Related]
13. Structural definition of a potent macrophage activating factor derived from vitamin D3-binding protein with adjuvant activity for antibody production.
Yamamoto N
Mol Immunol; 1996 Oct; 33(15):1157-64. PubMed ID: 9070663
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF).
Yamamoto N; Suyama H; Yamamoto N; Ushijima N
Int J Cancer; 2008 Jan; 122(2):461-7. PubMed ID: 17935130
[TBL] [Abstract][Full Text] [Related]
15. Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients.
Yamamoto N; Naraparaju VR; Asbell SO
Cancer Res; 1996 Jun; 56(12):2827-31. PubMed ID: 8665521
[TBL] [Abstract][Full Text] [Related]
16. A defect in the inflammation-primed macrophage-activation cascade in osteopetrotic rats.
Yamamoto N; Lindsay DD; Naraparaju VR; Ireland RA; Popoff SN
J Immunol; 1994 May; 152(10):5100-7. PubMed ID: 8176226
[TBL] [Abstract][Full Text] [Related]
17. Improved preparation of group-specific component (Gc) protein to derive macrophage activating factor.
Morita Y; Wang R; Li X; Muramatsu T; Ueda M; Hachimura S; Takahashi S; Miyakawa T; Tanokura M
Protein Expr Purif; 2020 Nov; 175():105714. PubMed ID: 32738434
[TBL] [Abstract][Full Text] [Related]
18. A novel assay system for macrophage-activating factor activity using a human U937 cell line.
Ishikawa M; Inoue T; Inui T; Kuchiike D; Kubo K; Uto Y; Nishikata T
Anticancer Res; 2014 Aug; 34(8):4577-81. PubMed ID: 25075102
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF.
Yamamoto N; Suyama H; Nakazato H; Yamamoto N; Koga Y
Cancer Immunol Immunother; 2008 Jul; 57(7):1007-16. PubMed ID: 18058096
[TBL] [Abstract][Full Text] [Related]
20. Tumor cell alpha-N-acetylgalactosaminidase activity and its involvement in GcMAF-related macrophage activation.
Mohamad SB; Nagasawa H; Uto Y; Hori H
Comp Biochem Physiol A Mol Integr Physiol; 2002 May; 132(1):1-8. PubMed ID: 12062184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]